The Non-Steroidal Farnesoid X Receptor (FXR) Agonist GS-9674 Improves Liver Biochemistry and Decreases Serum Bile Acids in Patients with Primary Sclerosing Cholangitis (PSC): A Phase 2, Randomized, Placebo-Controlled Trial

HEPATOLOGY(2018)

引用 2|浏览24
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要